Last reviewed · How we verify
procalcitonin-guided antibiotic therapy
Procalcitonin-guided antibiotic therapy involves using procalcitonin levels to guide the initiation and discontinuation of antibiotic therapy in patients with suspected bacterial infections.
Procalcitonin-guided antibiotic therapy involves using procalcitonin levels to guide the initiation and discontinuation of antibiotic therapy in patients with suspected bacterial infections. Used for Community-acquired pneumonia, Hospital-acquired pneumonia, Ventilator-associated pneumonia.
At a glance
| Generic name | procalcitonin-guided antibiotic therapy |
|---|---|
| Sponsor | Capital Medical University |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Procalcitonin is a peptide hormone that is produced in response to bacterial infections. By measuring procalcitonin levels, healthcare providers can determine the likelihood of a bacterial infection and make informed decisions about antibiotic therapy. This approach aims to reduce unnecessary antibiotic use and minimize the development of antibiotic resistance.
Approved indications
- Community-acquired pneumonia
- Hospital-acquired pneumonia
- Ventilator-associated pneumonia
Common side effects
- Increased risk of antibiotic resistance
- Potential for delayed diagnosis and treatment of bacterial infections
Key clinical trials
- Impact of Rapid Pathogen Detection in ICU Patients With Suspected Pneumonia on Antimicrobial Therapy (PHASE2)
- AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection (NA)
- Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial) (PHASE3)
- KInetics of Procalcitonin to Reduce Unnecessary aNtibiotic Use - Comparing Procalcitonin Kinetics-guided and Absolute Procalcitonin Value-guided Antibiotic Initiation in Reducing Unnecessary Antibiotic Use in Critically Ill Patients (NA)
- Procalcitonin and Duration of AntiBiotherapy In Late Onset Sepsis of Neonate (NA)
- An Antibiotic Protocol Guided by a Multimodal Approach in AECOPD With Pneumonia in Intensive Care (NA)
- Procalcitonin Aided Antimicrobial Therapy vs Standard of Care (NA)
- PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: